Krebs Biochemicals & Industries Ltd
NSE: KREBSBIO BSE: 524518
₹59.23
+0.47 (0.80%)
Sun, 22 Nov 2026, 09:12 pm
Market Cap (in Cr)126.95
PE Ratio0
Dividend0
Krebs Biochemicals & Industries Analysis
dividend
Pros
Cons
- Unable to evaluate Krebs Biochemicals & Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Krebs Biochemicals & Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
Pros
Cons
- Krebs Biochemicals & Industries's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Krebs Biochemicals & Industries has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.9% each year.
- Krebs Biochemicals & Industries has less than a year of cash runway based on current free cash flow.
- Operating cash flow is negative therefore debt is not well covered.
- Krebs Biochemicals & Industries has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Krebs Biochemicals & Industries's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Krebs Biochemicals & Industries's debt level has increased considering it has negative shareholder equity.
- Krebs Biochemicals & Industries has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
Pros
- The tenure for the Krebs Biochemicals & Industries board of directors is about average.
- Avinash's compensation has been consistent with company performance over the past year, both up more than 20%.
Cons
- Avinash's remuneration is higher than average for companies of similar size in India.
- The average tenure for the Krebs Biochemicals & Industries management team is less than 2 years, this suggests a new team.
misc
Pros
Cons
- Krebs Biochemicals & Industries is not covered by any analysts.
past
Pros
Cons
- Unable to compare Krebs Biochemicals & Industries's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Krebs Biochemicals & Industries does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Krebs Biochemicals & Industries has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Krebs Biochemicals & Industries improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Krebs Biochemicals & Industries has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Krebs Biochemicals & Industries's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
Pros
- KREBSBIO outperformed the Market in India which returned -14.5% over the past year.
- NSEI:KREBSBIO is up 11.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:KREBSBIO is up 11.8% outperforming the market in India which returned 8% over the past month.
Cons
- Krebs Biochemicals & Industries has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Krebs Biochemicals & Industries is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Krebs Biochemicals & Industries is loss making, we can't compare the value of its earnings to the India market.
- KREBSBIO underperformed the Pharmaceuticals industry which returned 26.7% over the past year.